For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 ...

Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...

Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation ...

Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Jeremie Calais, MD, comments on how PSMA PET scans have changed the treatment landscape for patients with mCRPC and describes the process for obtaining a PSMA PET scan, including what patients should ...

On 16 January 2026, Telix Pharmaceuticals announced that the first U.S. patient had been dosed in BiPASS, a Phase 3 trial evaluating Illuccix and Gozellix PSMA-PET imaging alongside MRI for initial ...

Prostate cancer is the most common cancer in men and the second-leading cause of cancer-related deaths in men in the US. There’s a new and promising diagnostic procedure for prostate cancer known as ...

Lantheus’ product, PYLARIFY (piflufolastat F18) injection, is the first and only commercially available and FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass., ...